The vaccine is designed to spur the immune system's production of anti-Ebola antibodies, and people developed them within four weeks of getting the shots at the National Institutes of Health. Anthony Fauci, director of NIH's National Institute of Allergy and Infectious Diseases, whose employees led the work. Earlier this month, Fauci told Congress this...» Read More
Critics have been saying for years that big pharma's been pi..., er, throwing away money on relatively unproductive research and development of new drugs. But a new study shows urine could eventually provide a new revenue stream.
Remember 1993 and health care? It was doomed because Americans did not want Big Government running one more part of their lives. Why? Because Government doesn’t do things very well – it’s as simple as that.
The London “Daily Mail” has published photos of the flames and aftermath at the Austrian vacation home of Novartis CEO Dr. Daniel Vasella. The arsonists claim to have used nearly 16 gallons of gasoline to ignite the blaze. It was reportedly set at 3:30 in the morning.
On this website for something called "Bite Back" magazine a group identifying itself as MFAH Austria is claiming responsibility for the recent attacks on Swiss drugmaker Novartis and its employees, including CEO Dr. Daniel Vasella.
Pressed by industry lobbyists, White House officials on Wednesday assured drug makers that the administration stood by a behind-the-scenes deal to block any Congressional effort to extract cost savings from them beyond an agreed-upon $80 billion.
Reports surfaced this morning that animal rights activists are suspected of setting fire to and badly damaging the vacation home of Novartis CEO Daniel Vasella in the wee hours of the morning yesterday.
This Friday Merck and Schering-Plough shareholders are set to vote on the mega-merger. When companies co-mingle it's standard operating procedure for heads to roll. So-called "cost-saving synergies" are a big reason why deals like this get done. But this out-of-the-blue departure seems to have nothing to do with that.
The biggest barrier to improved cancer treatments is that almost no adult cancer patients — just 3 percent — participate in studies of cancer treatments, mostly new drugs or drug regimens.
Everyone’s talking about the July stock market rally. And, of course, you can’t overlook the outperformance of biotech—big and small.
Government-run insurance could not be worse than what small businesses already face.
The drug companies help pay my salary. Not directly, of course (although I bet there are conspiracy theorists out there who are probably convinced they do), but they undoubtedly contribute a sizeable amount of advertising dollars to the company I work for.
I'm betting somebody's blood pressure at Eli Lilly headquarters in Indianapolis today went through the roof.
What a week! And there's still one day left. Human Genome Sciences and Orexigen got the party started on Monday with their Lupus and diet drug data, respectively. Onyx Pharmaceuticals was a surprise guest with its mid-stage breast cancer results on Wednesday. Bristol-Myers Squibb cranked up the volume late yesterday with its two-bagger for Medarex. And then this morning Celgene announced it had stopped a multiple myeloma study early because the drug appears to be working so well.
A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?
Recently, Merck came out with the first vaccine for shingles called Zostavax. But it had manufacturing and supply issues that hurt the launch. In its earnings press release today, Merck says as of last month it has "resumed normal shipping schedules for Zostavax."
The Food and Drug Administration today announced that Teva Pharmaceutical Industries is voluntarily recalling two lots of the anesthetic Propofol because there are higher levels of potentially fatal endotoxins...Propofol is the same drug that was reportedly found in Michael Jackson’s house.
Carl Icahn and all of the Elanians should be happy. Biogen Idec today reported encouraging trends regarding its all-important multiple sclerosis drug Tysabri.
Man, time flies. I can't believe almost a year has passed since the incident at ICAD. That's the big Alzheimer's Disease scientific research conference that was held in Chicago in late July last year. This year, it's in Vienna and it's going on right now.
For years now, but especially in recent months, I've been covering the obesity epidemic. I regularly report on the statistics and the experimental drug data, detached and "objective" as I think any good reporter should be. It just didn't occur to me that the target population might include my sister.
I was wrong. I'd blogged a few times that I thought the FDA might have a problem with "Effient," Eli Lilly's proposed name for its bloodthinner, because it was too close to efficient and all the connotations that would have.